Navigation Links
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Date:9/18/2007

LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications for these drugs and fueling continued rapid market growth. In addition to the seven marketed ErbB-pathway inhibitors, more than 50 novel agents targeting this pathway are in development.

"The ErbB Pathway in Cancer" is a series of comprehensive reports published in Future Oncology, New Medicine's premiere newsletter. Future Oncology provides analysis of critical issues in global cancer R&D, clinical practices, markets, and business and company developments. The series covers every aspect of the EGFr/HEr2 inhibitor marketplace, including:

-- Markets (USA and ROW) of approved drugs and forecasts

-- Treatment costs in the USA and ROW

-- Detailed ErbB pathway analyses

-- Associations of ErbB expression and mutations with specific indications

-- EGFr/HEr2-based diagnostic/theragnostic technologies and products

-- Detailed profiles of currently approved drugs

-- Comprehensive reviews of current use of approved drugs by indication

-- Comprehensive reviews of new indications of approved drugs

-- Protocols and interim and final results from clinical trials combining

approved ErbB pathway inhibitors with novel agents.

-- Detailed profiles of over 50 agents in development targeting the ErbB

pathway, including protocols and interim and final results from

hundreds of trials

This series, published in 5 parts, is available for purchase in electronic PDF or hard copy format.


'/>"/>
SOURCE New Medicine
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
4. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
5. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
10. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
11. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):